Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma

Background/Aims: Hodgkin Lymphoma (HL) has become one of the most treatable cancers, with more than 80% patients in the advanced stage being cured through improvement of therapeutic regimens. Nevertheless, some treatments were accompanied with toxicities.Methods: In the current study, a network meta...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fajun Pei, Yang Yu, Bin Dong, Hui Guan, Xinzhe Dong, Fen Zhao
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	hodgkin lymphoma chemotherapy efficacy randomized controlled trial network meta-analysis Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/bf77a664bda34765b159ad5a49981c0e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bf77a664bda34765b159ad5a49981c0e
record_format	dspace
spelling	oai:doaj.org-article:bf77a664bda34765b159ad5a49981c0e2021-11-16T05:18:05ZEfficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma1663-981210.3389/fphar.2021.694545https://doaj.org/article/bf77a664bda34765b159ad5a49981c0e2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphar.2021.694545/fullhttps://doaj.org/toc/1663-9812Background/Aims: Hodgkin Lymphoma (HL) has become one of the most treatable cancers, with more than 80% patients in the advanced stage being cured through improvement of therapeutic regimens. Nevertheless, some treatments were accompanied with toxicities.Methods: In the current study, a network meta-analysis (NMA) was conducted to compare the efficacies and toxicities of different chemotherapy regimens for advanced Hodgkin lymphoma (HL). We reviewed PubMed and EMBASE databases from inception to May 2018, and identified randomized controlled trials (RCTs) in which advanced HL patients received chemotherapy. Fourteen eligible RCTs published between 1992 and 2017 were enrolled in this NMA. These studies included a total of 5,964 HL patients, and assessed at least one of seven different chemotherapy regimens. Direct and indirect evidence was combined to calculate odds ratios (ORs) and 95% confidence intervals (95% CIs), and to establish a surface under the cumulative ranking (SUCRA) curve.Results: A cluster analysis was performed to evaluate efficacies and toxicities of different regimens. The COPP + ABVD (cyclophosphamide + vincristine + procarbazine + prednisone + doxorubicin + bleomycin + vinblastine + dacarbazine) regimen had the highest SUCRA partial response and overall remission rate values, while the ABVD regimen resulted in the lowest incidences of anemia, thrombocytopenia, neutropenia, and leucopenia.Conclusion: Cluster analysis revealed that COPP + ABVD had the best efficacy against advanced HL among the seven regimens, and ABVD had the lowest toxicity.Fajun PeiYang YuYang YuBin DongHui GuanXinzhe DongFen ZhaoFen ZhaoFrontiers Media S.A.articlehodgkin lymphomachemotherapyefficacyrandomized controlled trialnetwork meta-analysisTherapeutics. PharmacologyRM1-950ENFrontiers in Pharmacology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	hodgkin lymphoma chemotherapy efficacy randomized controlled trial network meta-analysis Therapeutics. Pharmacology RM1-950
spellingShingle	hodgkin lymphoma chemotherapy efficacy randomized controlled trial network meta-analysis Therapeutics. Pharmacology RM1-950 Fajun Pei Yang Yu Yang Yu Bin Dong Hui Guan Xinzhe Dong Fen Zhao Fen Zhao Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma
description	Background/Aims: Hodgkin Lymphoma (HL) has become one of the most treatable cancers, with more than 80% patients in the advanced stage being cured through improvement of therapeutic regimens. Nevertheless, some treatments were accompanied with toxicities.Methods: In the current study, a network meta-analysis (NMA) was conducted to compare the efficacies and toxicities of different chemotherapy regimens for advanced Hodgkin lymphoma (HL). We reviewed PubMed and EMBASE databases from inception to May 2018, and identified randomized controlled trials (RCTs) in which advanced HL patients received chemotherapy. Fourteen eligible RCTs published between 1992 and 2017 were enrolled in this NMA. These studies included a total of 5,964 HL patients, and assessed at least one of seven different chemotherapy regimens. Direct and indirect evidence was combined to calculate odds ratios (ORs) and 95% confidence intervals (95% CIs), and to establish a surface under the cumulative ranking (SUCRA) curve.Results: A cluster analysis was performed to evaluate efficacies and toxicities of different regimens. The COPP + ABVD (cyclophosphamide + vincristine + procarbazine + prednisone + doxorubicin + bleomycin + vinblastine + dacarbazine) regimen had the highest SUCRA partial response and overall remission rate values, while the ABVD regimen resulted in the lowest incidences of anemia, thrombocytopenia, neutropenia, and leucopenia.Conclusion: Cluster analysis revealed that COPP + ABVD had the best efficacy against advanced HL among the seven regimens, and ABVD had the lowest toxicity.
format	article
author	Fajun Pei Yang Yu Yang Yu Bin Dong Hui Guan Xinzhe Dong Fen Zhao Fen Zhao
author_facet	Fajun Pei Yang Yu Yang Yu Bin Dong Hui Guan Xinzhe Dong Fen Zhao Fen Zhao
author_sort	Fajun Pei
title	Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma
title_short	Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma
title_full	Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma
title_fullStr	Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma
title_full_unstemmed	Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma
title_sort	efficacies and toxicities of seven chemotherapy regimens for advanced hodgkin lymphoma
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/bf77a664bda34765b159ad5a49981c0e
work_keys_str_mv	AT fajunpei efficaciesandtoxicitiesofsevenchemotherapyregimensforadvancedhodgkinlymphoma AT yangyu efficaciesandtoxicitiesofsevenchemotherapyregimensforadvancedhodgkinlymphoma AT yangyu efficaciesandtoxicitiesofsevenchemotherapyregimensforadvancedhodgkinlymphoma AT bindong efficaciesandtoxicitiesofsevenchemotherapyregimensforadvancedhodgkinlymphoma AT huiguan efficaciesandtoxicitiesofsevenchemotherapyregimensforadvancedhodgkinlymphoma AT xinzhedong efficaciesandtoxicitiesofsevenchemotherapyregimensforadvancedhodgkinlymphoma AT fenzhao efficaciesandtoxicitiesofsevenchemotherapyregimensforadvancedhodgkinlymphoma AT fenzhao efficaciesandtoxicitiesofsevenchemotherapyregimensforadvancedhodgkinlymphoma
_version_	1718426690964684800

Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma

Ejemplares similares